company background image
ALON

Onxeo ENXTPA:ALONX Stock Report

Last Price

€0.30

Market Cap

€33.8m

7D

-5.9%

1Y

-46.1%

Updated

25 Sep, 2022

Data

Company Financials
ALONX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ALONX Stock Overview

Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide.

Onxeo SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Onxeo
Historical stock prices
Current Share Price€0.30
52 Week High€0.56
52 Week Low€0.28
Beta1.16
1 Month Change-10.44%
3 Month Change-10.44%
1 Year Change-46.11%
3 Year Change-50.25%
5 Year Change-83.27%
Change since IPO-97.71%

Recent News & Updates

Shareholder Returns

ALONXFR BiotechsFR Market
7D-5.9%-13.4%-4.8%
1Y-46.1%-56.8%-14.1%

Return vs Industry: ALONX exceeded the French Biotechs industry which returned -56.8% over the past year.

Return vs Market: ALONX underperformed the French Market which returned -14.1% over the past year.

Price Volatility

Is ALONX's price volatile compared to industry and market?
ALONX volatility
ALONX Average Weekly Movement5.4%
Biotechs Industry Average Movement7.2%
Market Average Movement4.8%
10% most volatile stocks in FR Market8.9%
10% least volatile stocks in FR Market2.7%

Stable Share Price: ALONX is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: ALONX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199736Shefali Agarwalhttps://www.onxeo.com

Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform.

Onxeo SA Fundamentals Summary

How do Onxeo's earnings and revenue compare to its market cap?
ALONX fundamental statistics
Market Cap€33.82m
Earnings (TTM)-€12.64m
Revenue (TTM)€3.47m

9.7x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALONX income statement (TTM)
Revenue€3.47m
Cost of Revenue€416.00k
Gross Profit€3.06m
Other Expenses€15.70m
Earnings-€12.64m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.11
Gross Margin88.02%
Net Profit Margin-363.89%
Debt/Equity Ratio44.0%

How did ALONX perform over the long term?

See historical performance and comparison